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Abstract
Somatic mutations in the isocitrate dehydrogenase (IDH)1/2 genes endow encoding pro-
teins with neomorphic activity to produce the potential oncometabolite, 2-hydroxyglutarate
(2-HG), which induces the hypermethylation of histones and DNA. The incidence of IDH1/2
mutations in cartilaginous tumors was previously shown to be the highest among various
types of tumors, except for those in the central nervous system. Mutations have been
detected in both benign (enchondromas) and malignant (chondrosarcomas) types of carti-
laginous tumors, whereas they have rarely been found in other mesenchymal tumors such
as osteosarcomas. To address this unique tumor specificity, we herein examined the effects
of IDH1 R132C, which is the most prevalent mutant in cartilaginous tumors, on the differenti-
ation properties of human mesenchymal stem cells (hMSCs). The induction of the IDH1
R132C gene into MSCs markedly increased the amount of 2-HG and up-regulated global
histone methylation. The induction of IDH1 R132C promoted the chondrogenic differentia-
tion of hMSCs by enhancing the expression of SOX9 and COL2A1 genes in association
with an increase in the active mark (H3K4me3), but disrupted cartilage matrix formation. On
the other hand, IDH1 R132C inhibited expression of the ALPL gene in association with an
increase in the repressive mark (H3K9me3), and subsequently inhibited the osteogenic
properties of hMSCs and human osteosarcoma cells. Since osteogenic properties are an
indispensable feature for the diagnosis of osteosarcoma, the inhibitory effects of IDH1
R132C on osteogenic properties may contribute to the lack of osteosarcomas with the IDH1
PLOSONE | DOI:10.1371/journal.pone.0131998 July 10, 2015 1 / 15
OPEN ACCESS
Citation: Jin Y, Elalaf H, Watanabe M, Tamaki S,
Hineno S, Matsunaga K, et al. (2015) Mutant IDH1
Dysregulates the Differentiation of Mesenchymal
Stem Cells in Association with Gene-Specific Histone
Modifications to Cartilage- and Bone-Related Genes.
PLoS ONE 10(7): e0131998. doi:10.1371/journal.
pone.0131998
Editor:Wan-Ju Li, University of Wisconsin-Madison,
UNITED STATES
Received: January 15, 2015
Accepted: June 9, 2015
Published: July 10, 2015
Copyright: © 2015 Jin et al. This is an open access
article distributed under the terms of the Creative
Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any
medium, provided the original author and source are
credited.
Data Availability Statement: All relevant data are
within the paper and its Supporting Information files.
Funding: This work was supported by Grants-in-Aid
for Scientific Research from the Japan Society of the
Promotion of Science to TO and JT (#25670642)
(http://mhlw-grants.niph.go.jp/). One of the co-
authors, Makoto Watanabe, is an employee of
Shimadzu Cooperation. The Life Science Research
Center, Shimadzu Cooperation provided support in
the form of his salary, but did not have any additional
role in the study design, data collection and analysis,
R132C mutation. These results suggested that IDH1 R132C contributed to the formation of
cartilaginous tumors by dysregulating the chondrogenic and osteogenic differentiation of
hMSCs via gene-specific histone modulation.
Introduction
Isocitrate dehydrogenases (IDH) are metabolic enzymes that catalyze the oxidative decarboxyl-
ation of isocitrate to α-ketoglutarate (α-KG), and consist of a gene family with three members:
IDH1, IDH2 and IDH3, the first of which localizes in the cytoplasm while the latter two localize
in mitochondria [1,2]. Somatic heterozygous IDH1 or IDH2mutations have frequently been
detected in glioma/glioblastomas by genome wide mutation searches [3,4]. Subsequent studies
revealed that IDHmutations were extremely rare in primary (de novo) glioblastomas, but were
common in recurrent glioblastomas developing secondary to low-grade tumors, which also fre-
quently have IDHmutations [5]. These findings suggested that IDHmutations are an early
event in gliomagenesis and persist during progression to recurrent glioblastomas.
IDH1mutations typically result in substitutions at codon R132, whereas IDH2mutations
affect codon R172 or R140 [1,2]. Although a number of different mutants have been identified
to date, the most common and important feature of mutant proteins is their neomorphic
enzyme activity, which converts α-KG to 2-hydroxyglutarate (2-HG) [6]. Since 2-HG and α-
KG are structurally identical, except that the C2 carbonyl group in α-KG is replaced by a
hydroxyl group in 2-HG, 2-HG competes with α-KG and inhibits various α-KG-dependent
enzymes including Jumonji-C domain-containing histone demethylase [7], the ten-eleven
translocation (TET) family of 5-methylcytosine hydroxylases [8], and prolyl hydroxylase
domain-containing proteins (PHD) [6]. These inhibitory effects induce aberrant DNA and his-
tone methylation [7], and stabilize hypoxia inducible factor-1α, which then induces angiogene-
sis by up-regulating the VEGF gene [6]. Due to this pleiotropic function for dysregulating
biological events, 2-HG is regarded as an oncometabolite that exerts tumor-inducing actions,
and searches for IDH gene mutations have been performed in various types of malignancies
[1,2]. IDH1/2mutations have consequently been detected in acute myeloid leukemia (AML)
[9,10] and myelodysplastic disorders [11], but rarely in thyroid [12], prostate, B cell lymphoma,
and colorectal carcinomas [13].
In 2011, cartilaginous tumors were added to the list of tumors with IDH1mutations [14,15]
as tumors with the highest frequency IDHmutations, except for central nervous system tumors
[16]. Cartilaginous tumors have been defined as tumors that produce cartilage-like tissues and
consist of benign (such as enchondroma) and malignant (including conventional chondrosar-
coma) tumors [17]. IDHmutations were found in both tumors with equal frequency [16], sug-
gesting the role of IDHmutants in the initial step of transformation; however, the precise role
of these mutants currently remains unknown. Most cartilaginous tumors, either benign or
malignant, develop from the intramedullary region, and tumor cells have a chondrocyte-like
morphology [17]. These clinical findings suggest that cells in bone marrow that have the ability
to differentiate into chondrogenic cells are precursors of this type of tumor. Mesenchymal stem
cells (MSCs) are defined as cells with differentiation properties for osteo-, adipo-, and chondro-
genic lineages, and reside among bone marrow stromal cells [18], which are, therefore, reason-
able candidates as the precursor cells of cartilaginous tumors.
We herein investigated the role of mutant IDH1 in the development of cartilaginous tumors
using MSCs. We found that IDH1 mutants modified the differentiation properties of MSCs as
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well as the histone methylation of cartilage- and bone-related genes in a gene-specific manner.




The experimental protocols dealing human subjects were approved by the Ethics Committee of
the Department of Medicine and Graduate School of Medicine, Kyoto University. Written
informed consent was provided by each donor.
Tissue specimens
Tumor tissue samples were obtained from patients with enchondromas (3 cases fromMaffucci
syndrome, 5 from Ollier’s disease, and 15 from solitary cases), chondrosarcomas (54), osteo-
chondromas (7), and osteosarcomas (29) via either biopsy or resection in Kyoto University
Hospital. Histological analyses were performed in all the samples, and showed that more than
90% of each tissue was composed of tumor cells.
DNA extraction and direct DNA sequencing
High molecular weight genomic DNA was isolated from tumor tissues by standard phenol-
chloroform extraction methods. DNA was amplified by PCR using two primer sets for exon 4
of the IDH1 gene and exon 4 of the IDH2 gene. The sequences of the primers used to detect
IDHmutations have been reported previously [16]. PCR products were then sequenced on a
3500XL Genetic Analyzer (Applied Biosystems, Forester City, CA) with the Big Dye Termina-
tor v3.1 Cycle Sequencing Kit (Applied Biosystems) according to standard procedures.
Primary cultured cells
Bone marrow-derived MSCs from three donors (BM01, BM02, and BM03) were isolated with
centrifugation and adhered to plastic dishes [19]. MSCs were cultured in α-minimal essential
medium with GlutaMAX (Life Technologies, Carlsbad, CA) supplemented with 10% fetal
bovine serum (HyClone., South Logan, UT, USA), 100 U/ml penicillin, and 100 mg/ml strepto-
mycin. Expanded cells were characterized with cell surface markers and differentiation abilities
as MSCs (Data not shown). Cells passaged less than five times were used in experiments.
Establishment of the pLenti6-IDH1 construct and lentiviral infection
The entire coding region of the human IDH1 gene (NM_005896) with the N-terminal Flag and
HA tag was cloned into the pDONR221 entry vector (Life Technologies). The IDH1 R132C
mutant was generated using site-directed mutagenesis. Therefore, primers were created and
used on wild type IDH1 cDNA in pDONR221. The wild type and R132C mutant of IDH1 were
transferred into the pLenti6/V5-DEST gateway vector (Life Technologies) via the LR-reaction,
resulting in pLenti6-Flag-HA-IDH1 (wt or R132C). The lentivirus was generated by transfect-
ing 293FT cells with Lipofectamine 2000 (Life Technologies). hMSCs were infected with the
lentivirus supernatant and selected with 5 μg/ml blasticidin (Invivogen, San Diego, CA).
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Intracellular metabolite extraction and quantification of 2-HG with
GC-MS
Cultured cells were washed twice with ice-cold 0.9% NaCl aqueous solution. These cells were
quenched with 1.5 ml of 80% methanol aqueous solution and chilled at -20°C for 5 min. They
were then scraped off, resuspended in 80% methanol aq., and transferred to sample tubes.
After centrifugation at 9,000×g for 5 min, the supernatant was collected, the cell pellet was
resuspended in 0.5 ml of 80% methanol aq., and centrifuged at 9,000×g for 5 min. The superna-
tants were pooled and dried with SpeedVac. The pellets were dissolved with 80 μl of pyridine
(Wako Pure Chemical Industries, Ltd., Osaka, Japan). After the addition of 40 μl of MSTFA
(N-Methyl-N-TMS-Trifluoroacetamide) (GL Science Inc., Tokyo, Japan), the samples were
incubated for 30 min at 30°C. The samples were centrifuged at 3,000×g for 5 min and the
supernatants were subjected to a Gas chromatography-Mass spectrometry (GC-MS) analysis.
The GC-MS analysis was performed with GCMS QP2010 Ultra (Shimadzu Corporation,
Kyoto, Japan). One microliter of the sample was injected with an auto injector AOC-20i (Shi-
madzu Corporation). After an initial 2 min at 80°C, the temperature was increased to 147°C at
a rate of 15°C/min, followed by an additional constant temperature period at 330°C for 5 min.
Gas chromatography was performed with a DB-5 column (30 m×0.25 mm I.D.) (Agilent Tech-
nologies, CA). Full scan mass spectra were acquired from m/z 85 to 460.
Establishment of the osteosarcoma cell line with the doxycycline
inducible IDH1 gene by the PiggyBac transposon system
The entire coding region of the human IDH1 gene was cloned into the pDONR221 entry vec-
tor. The IDH1 R132C mutant was generated using site-directed mutagenesis. The wild type
and R132C mutant of IDH1 were transferred into KW111/GW, a derivative of PB-TET con-
taining the rtTA transactivator [20], via the LR-reaction, resulting in KW111-IDH1 (WT or
R132C). One microgram of each KW111-IDH1 and PBaseII plasmid DNA was co-transfected
into human osteosarcoma cells (ANOS) [21] using the FuGENE HD transfection reagent (Pro-
mega, Tokyo, Japan). After being selected with G418 (500 μg/ml), drug-resistant cells were
used as a bulk population, and the expression of each IDH gene was induced by doxycycline
(0.2 μg/ml).
Cell proliferation assay
A cell proliferation assay was performed using Cell Counting Kit-8 (Dojindo, Kumamoto,
Japan). Cells were plated on 96-well plates at 1000 cells per well and cultured in growth
medium. On days 1 and 8, 100 μl of growth medium with 10% CCK-8 solution was added to
the wells, and the plate was incubated for a further 3 hours. Cell numbers in triplicate wells
were then measured as the O.D. at 450 nm of reduced CCK-8.
Western blotting
Western blotting was performed as described [22]. The primary antibodies used were as fol-
lows: #8137 for IDH1 (Cell Signaling Technology, Danvers, MA), #07–473 for H3K4me3, and
#07–449 for H3K27me3, #07–690 for pan H3 (Millipore, Billerica, MA), and ab8898 for
H3K9me3 (Abcam, Tokyo, Japan). Blots were probed with HRP-conjugated goat anti-mouse
IgG or goat anti-rabbit IgG (Cell Signaling).
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Reverse transcription (RT) and quantified PCR (qPCR)
Total RNA was isolated from cells with the RNeasy Mini Kit (QIAGEN, Valencia, CA) and
1 μg of total RNA was used in the RT reaction with the SuperScript III first-strand synthesis
system (Life Technologies) according to the manufacturer`s instructions. The primers used in
qPCR were listed in S1 Table. qPCR was performed in triplicate using THUNDERBIRD SYBR
qPCRMix (QPS-201, TOYOBO, Japan).
Induction of differentiation
Osteogenic differentiation was induced in growth medium supplemented with 0.1 μM dexa-
methasone, 50 μM ascorbic acid, and 10 mM β-glycerophosphate as previously described [22].
After a 14-day induction, calcium deposits were visualized by alizarin red staining, and the cal-
cium content was quantified based on the OCPC method.
Chondrogenic differentiation was induced in the pellet culture (2.5× 105 cells/pellet) with
hMSC Chondrocyte Differentiation Medium (PT-3003, Lonza, Tokyo, Japan) supplemented
with 10 ng/ml TGFβ3 for 21 days in a 15-ml centrifuge tube (#430791, Corning, NY, USA) or
Lipidure-Coat 96-well plate (#81100525, Thermo Scientific, Yokohama, Japan), as previously
described [22].
Chromatin immunoprecipitation (ChIP) assay
A ChIP assay was performed as previously described [21]. Briefly, cross-linking was achieved by
incubating cells in growth medium with formaldehyde at a final concentration of 1% for 10 min
at room temperature. The protein-DNA complex was then extracted by lysis buffer (1% SDS;
10 mM EDTA; 50 mM Tris-HCl) and sonicated to shear DNA into 300–500 bp fragments. After
centrifugation, the supernatants were incubated with antibodies at 4°C overnight. The next day,
the complexes were precipitated by incubating with Protein G beads (Millipore) before centrifu-
gation. After several washing steps, the chromatin-antibody complex was eluted with elution
buffer (1% SDS, 0.1 M CH3CO2Na, 10 mMDTT), and DNA was separated from proteins with
200 mMNaCl at 65°C overnight, and subsequently with 50 μg/ml protein K at 45°C for 1 hr.
DNA was purified with phenol/chloroform extraction and ethanol precipitation. The promoters
or enhancer region were amplified by qPCR and mean enrichment relative to input was com-
puted. The following primers were used to amply the SOX9 promoter [23] (Accession No.:
NG_012490): 5`-TTTCC ATTGA CTCCC TTTGC-3`and 5`-TGCCT GCAAA AGTGC TTAG
A-3`, the COL2A1 promoter [24] (Accession No.: NG_008072): 5`-CTGCT CCTTT CTACC
GCTTT-3`and 5`-AGTTC TGCCG GAGTT GGAG-3`, the COL2A1 enhancer [25] (Accession
No.: NG_008072): 5`-GCTCC TCCGT CCACA CCT-3`and 5`-GGCTC GCTCA CAGAC
ACC-3`, and the ALPL promoter [26] (Accession No.: NG_008940): 5`-GGTCC CCTTC TG
CTT CTTCT-3`and 5`-CGTCT CTTTG TCTGC CTTCC-3`.
Knock-down of SOX9 with small interfering RNAs (siRNAs)
Two siRNAs against the SOX9 gene, siSOX9#1 (s13307, CGCTCACAGT- ACGACTACAtt)
and siSOX9#2 (s13308, AGCCCGATCTGAAGAAGGAtt), were obtained from Silencer Select
Pre-designed siRNA (Life Technology) and transfected into IDH1 R132C hMSCs (5×105 cells)
using Lipofectamine RNAiMAX (Life Technologies). Silencer Select Negative Control siRNA
#1 (#4390843) was used as a control.
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Statistical analysis
All results are the average of three independent experiments and are presented as the
mean ± SE; results shown as the average of technical replications are presented as the
mean ± SD. P values were calculated using the Student`s t-test or Dunnett multiple comparison
test, and p values0.05 were considered significant.
Results
Mutation spectrum of IDH1/2 genes in bone tumors of Japanese patients
To obtain the IDH1/2mutation spectrum in our samples, 77 cartilaginous tumors, 7 osteo-
chondromas, and 29 osteosarcomas were analyzed by direct sequencing. Three types of muta-
tions caused three types of mutant IDH1 (R132C, R132G, and R132H) genes while four types
of mutations causing three types of mutant IDH2 (R172S, R172T, and R172W) genes in carti-
laginous tumors (S1 Fig); however, no mutations were detected in osteochondromas or osteo-
sarcomas (Tables 1 and Table 2).
Of these mutations, 69% were detected in the IDH1 gene and 31% in the IDH2 genes. Fur-
thermore, IDH1 R132C was the most frequent mutation in this series. This mutation spectrum
was consistent with previous findings [16].
Table 1. Mutation spectrum of IDH1/2 genes in cartilaginous tumors.
Gene Type of mutations Base change No. of tumors with mutations (%)
IDH1 R132C CGT>TGT 16 (44.4)
IDH1 R132G CGT>GGT 7 (19.4)
IDH1 R132F CGT>CTT 2 (5.6)
IDH2 R172S AGG>AGC 4 (11.1)
IDH2 R172S AGG>AGT 4 (11.1)
IDH2 R172T AGG>ACG 2 (5.6)
IDH2 R172W AGG>TGG 1 (2.8)
doi:10.1371/journal.pone.0131998.t001
Table 2. Mutation spectrum of IDH1/2 genes in each type of cartilaginous tumor.
Diagnosis No. of tumors with mutation /No. of analyzed
tumors (%)
Type of mutant (No. of tumor with each mutant)
Enchondroma Maffucci syndrome 1/3(33.3) R132C(1)
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2-HG produced by IDH1 R132C induced histone methylation in hMSCs
Since the R132C mutant of IDH1 was the most prevalent mutant in cartilaginous tumors, we
decided to investigate its effects on the differentiation properties of hMSCs. Lentiviral expres-
sion vectors containing the wild type or IDH1 R132C gene were introduced into each of three
primary hMSCs. No significant difference was observed in the growth properties of transfected
hMSC between wild-type IDH1 and IDH1 R132C, whereas both significantly affected the
growth properties of hMSCs (S2 Fig). The GC-MS analysis confirmed the production of 2-HG
in BM01 cells expressing IDH1 R132C (Fig 1A). Similar results were obtained in the other two
hMSCs (data not shown), and hMSCs expressing IDH1 R132C produced markedly larger
amounts of 2-HG than cells expressing the exogenous wild-type IDH1 gene, in which the rela-
tive amount of 2-HG was equal to that in parental or cells infected with the empty vector
(Fig 1B). To confirm the effects of 2-HG produced by IDH1 R132C, global histone methylation
was analyzed by western blotting using antibodies against each type of methylated histone (Fig
1C). The amounts of active (H3K4me3) and repressive marks (H3K9me3 and H3K27me3)
were increased in cells expressing IDH1 R132C, whereas no significant differences were
observed in cells expressing wild-type exogenous IDH1 (Fig 1D). These results indicated that
infected IDH1 R132C exerted its function to produce 2-HG and subsequently induced histone
methylation.
Fig 1. IDH1 R132C produced 2-HG and increased global histonemethylation in hMSCs. A. Detection of
2-HG by GC-MS. Intracellular 2-HG was detected in the extracts of BM01 cells expressing the IDH1R132C
gene. Peaks withm/z 246 and 247 were selected as quantification ions for glutamate and 2-HG, respectively.
B. Relative amount of 2-HG in hMSCs. The amount 2-HG and glutamate was measured by GC-MS in cell
extracts from each type of cell and the ratio was demonstrated. The mean ± SE from the results of three
donors was shown.C. Expression of active (H3K4me3) and repressive (H3K9me3 and H3K27me3) histone
marks. Protein lysates were prepared from each type of BM01 cell and used for western blotting to detect
exogenous (Exo) and endogenous (Endo) IDH1 and indicated histone H3. D.Quantitative analyses of active
and repressive histone marks. The expression level of each mark in infected hMSCs (EV, WT, or R132C)
was demonstrated as a value relative to those in parental hMSCs (Par). The mean ± SE from the results of
three donors was shown. Par, parental hMSC; EV, hMSCs infected with the empty vector; WT and R132C,
hMSCs infected with the vector containing the wild-type IDH1 or IDH1R132C gene, respectively. *, p<0.05
and **, p<0.01 by Dunnett`s multiple comparisons test compared to the parental cells.
doi:10.1371/journal.pone.0131998.g001
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IDH1 R132C enhanced the expression of chondrocyte-related genes,
but disturbed pellet formation after chondrogenic differentiation
Since IDH gene mutations were preferentially observed in cartilaginous tumors, we investi-
gated the effects of IDH1 R132C on the expression of cartilage-related genes in hMSCs (Fig 2).
Surprisingly, without the induction of chondrogenic differentiation, the expression levels of the
SOX9 gene, a master transcription factor for chondrogenesis, was up-regulated in hMSCs
expressing IDH1 R132C (Fig 2A). The expression of COL2A1 and COL10A1 genes, which
encode the major extracellular matrix (ECM) protein in cartilage, was also up-regulated (Fig
2A). As for the genes encoding other ECM proteins, the expression of the ACAN gene was
down-regulated (Fig 2A), whereas that of the COMP gene remained unchanged (data not
shown).
To evaluate the differentiation property of these hMSCs, 3-dimensional chondrogenic dif-
ferentiation assays were performed, which showed hMSCs expressing IDH1 R132C failed to
Fig 2. The effect of IDH1 R132C on chondrogenic properties of hMSCs. A. The mRNA expression of
SOX9, COL2A1, ACAN, andCOL10A1 genes in hMSCs. RNAs were extracted from each hMSC and
analyzed by qRT-PCR. Data were expressed as the mean value relative to that of parental cells after
normalizing to expression of the ACTB gene. Results are the mean ± SE from the results of three different
donors Representative photos of pellet formation after chondrogenic induction in 15 ml centrifuge tube (B)
and in ultralow adhesion 96-well plates (C). **, p<0.01 by Dunnett`s multiple comparisons test compared to
the parental cells. Par, EV, MT, and R132C were as described in the legend for Fig 1.
doi:10.1371/journal.pone.0131998.g002
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form tight cartilaginous pellets. All 10 samples prepared from parental, empty vector-, and
wild type IDH1-transduced BM01 cells successfully created tight pellets, whereas none of the
10 samples derived from BM01 cells expressing IDH1 R132C showed pellets (Fig 2B). Similar
results were obtained using ultralow adhesion plates, which showed the failure of IDH1 R132C
cells to make a spheroidal structure (Fig 2C). Identical results were obtained in the other two
hMSCs (data not shown), suggesting that IDH1 R132C disturbed the ability of cells to make
cartilaginous matrix.
IDH1 R132C inhibited the expression of ALPL gene and disturbed
mineralization after osteogenic induction
Then we examined the effects of IDH1 R132C on the osteogenic differentiation in hMSCs. The
expression of RUNX2 and Osterix genes was up-regulated in hMSCs by the introduction of
IDH1 R132C (Fig 3A). However, the expression of alkaline phosphatase, liver/bone/kidney
(ALPL) gene was markedly down-regulated in hMSC expressing IDH1 R132C (Fig 3A). ALPL
is a key enzyme in bone formation because it plays a critical role in the mineralization of the
extracellular matrix [27].
Consistent with this reduction in the expression of the ALPL gene, hMSCs expressing the
IDH1 R132C gene failed to form calcified nodules stained with Alizarin red (Fig 3B) and depos-
ited markedly lower amounts of Ca (Fig 3C) after the osteogenic induction, suggesting that
IDH1 R132C inhibited the osteogenic properties of hMSCs.
This inhibitory effect was analyzed further in an osteosarcoma cell line with the inducible
IDH1 gene. The induction of IDH1 R132C, but not wild-type IDH1, down-regulated the
expression of the ALPL gene (Fig 4A), and osteogenic differentiation properties were inhibited,
as determined by the lower amount Ca deposited (Fig 4B) and smaller number of Alizarin-red-
positive calcified nodules (Fig 4C), which was consistent with the results obtained in hMSCs.
IDH1 R132C differently regulated the expression of chondrocyte- and
osteocyte-related genes by diverse histone modification
To investigate whether these effects of IDH1 R132C on differentiation were related to its effects
on histone methylation, histone modifications in the promoter regions of SOX9, COL2A1, and
ALPL genes were investigated. Histones associated with the promoter region of the SOX9 gene
in parental hMSCs were mainly modified with the active mark (H3K4me3) and less with the
repressive marks (H3K9me3 and H3K27me3). The induction of IDH1 R132C markedly
increased the amount of H3K4me3; however, the effects on H3K9me3 or H3K27me3 were
hardly detected (Fig 5A). Similar results were observed for the promoter region of the COL2A1
gene (Fig 5B), in which both active and repressive (H3K27me3) marks was observed in paren-
tal cells. Although the induction of IDH1 R132C increased the amount of both marks, a signifi-
cant difference was only observed for the active mark. The results for the enhancer region of
the COL2A1 gene also showed the preferential up-regulation of the active mark (S3 Fig). The
up-regulation of the COL2A1 gene remained unchanged even when the expression of the SOX9
gene, its major regulator, was inhibited by siRNA (S4 Fig), suggesting that epigenetic modifica-
tions contributed significantly to its expression. In contrast, the effects of IDH1 R132C on the
ALPL gene were completely different. Although both active and repressive marks were detected
in the promoter region of the ALPL gene in parental cells, only the repressed mark (H3K9me3)
was increased by the expression of IDH1 R132C (Fig 5C). These effects of IDH1 R132C on his-
tone modification in each gene correlated well with the effects on the expression level of each
gene, suggesting that the effects of IDH1 R132C on the expression of three genes and subse-
quently on differentiation properties were via epigenetic modifications.
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Discussion
Certain metabolites have critical roles as regulators and co-factors of important enzymes in
various biological pathways, and recent cancer research disclosed that metabolic alterations
contributed to the initiation and development of malignant cells. 2-HG produced by mutant
IDH proteins is a prototype of these oncometabolites, and a number of studies have disclosed
the role of 2-HG in malignant transformation [1,2].
One interesting and still unanswered question regarding IDHmutations in cancer is their
tumor-type-specific prevalence. Mutations in IDH genes are the most frequent genetic abnor-
mality in central nervous system (CNS) tumors, but are extremely rare in other types of cancers
such as prostate and colorectal cancers [1,2]. Cartilaginous tumors frequently share mutations
in IDH genes with these in CNS tumors [16], even though these two tumor types are
Fig 3. The effect of IDH1 R132C on osteogenic properties of hMSCs. A. The mRNA expression of
RUNX2,OSX, ALPL andCOL1A1 genes in hMSCs. RNAs were extracted from each hMSC and analyzed by
qRT-PCR. Data are shown as a value relative to that of parental cells after normalizing to expression of the
ACTB gene.B. Calcium (Ca) deposition after osteogenic induction in each hMSC. Data were normalized to
the culture area. Results (A andB) are the mean ± SE from the results of three different donors.C. Calcified
nodule formation after osteogenic induction. Each type of BM01 cell was cultured under osteogenic induction
conditions and then stained with Alizarin Red S. **, p<0.01 by Dunnett`s multiple comparisons test
compared to the parental cells. Par, EV, MT, and R132C were as described in the legend for Fig 1.
doi:10.1371/journal.pone.0131998.g003
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Fig 4. IDH1 R132C inhibited the osteogenic differentiation of human osteosarcoma cells. A.mRNA
expression of the ALPL gene. RNAs were extracted from ANOS cells transduced with doxycycline (Dox)
inducible expression vectors containing the wild-type IDH1 (WT) or IDH1R132C (R132) gene before and
after osteogenic induction (OI) and analyzed by qRT-PCR. Data are shown as a value relative to that of
WT-ANOS cells before OI after normalizing to expression of the ACTB gene expression. **, p<0.01 by
Dunnett`s multiple comparisons test compared to theWT cells or R132C cells without Dox treatment.B.
Calcium (Ca) deposition after osteogenic induction in WT- and R132C-ANOS cells. Data were normalized to
the culture area. **, p<0.01 by the Student`s t-test. C. Calcified nodule formation after osteogenic induction.
WT- or R132C-ANOS cells were cultured under osteogenic induction conditions with or without doxycycline
and then stained with Alizarin Red S. Error bars indicate the average ± SD from three biological replicates.
doi:10.1371/journal.pone.0131998.g004
Fig 5. IDH1 R132C differentially regulated the expression of chondrocyte- and osteocyte-related
genes by gene-specific epigenetic modulation. Active and repressive histone marks associated with the
promoter regions of the SOX9 (A), COL2A1 (B), and ALPL (C) genes. The status of histone modification in
each hMSC (Par, EV, MT, or R132C, as described in the legend for Fig 1) was analyzed by chromatin
immunoprecipitation (ChIP) using antibodies against H3K4me3, H3K9me3, and H3K27me3. The target
region of each locus was shown in the scheme at the top of each graph. Data were presented by qPCR, and
the values were indicated relative to the input. Error bars reflect SD in 3 experiments. TSS, transcription start
site. **, p<0.01 by Dunnett`s multiple comparisons test compared to the parental cells.
doi:10.1371/journal.pone.0131998.g005
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histologically and developmentally different. This incidence may be related to many factors,
one of which may be their effects on differentiation through epigenetic modifications. Impaired
differentiation by mutant IDH has been reported in CNS, hematopoietic, and hepatocholangial
differentiation processes [28–30]. Therefore, we herein examined the effects of IDH1 R132C
on the differentiation properties of hMSCs, which presumably are precursors of cartilaginous
tumors. hMSCs with IDH1 R132C began to express the early (SOX9) and late (COL2A1 and
COL10A1) chondrogenic markers (Fig 2). After chondrogenic induction, however, cells
expressing IDH1 R132C failed to make cartilage-like pellets (Fig 2). The hydroxylation of pro-
line residues is an important step for collagen maturation, which reinforces its helical structure
and promotes its thermal stability [31]. This reaction was catalyzed by prolyl-4-hydroxylases,
which are regulated by α-KG and, therefore, inhibited by 2-HG [1,2]. A previous study demon-
strated that the maturation of type IV collagen was inhibited in IDH1 R132H knock-in mice,
resulting in fragile basement membranes [32], which may be relevant to our results on the car-
tilage matrix. Mutations in the COL2A1 gene itself have been identified in approximately one
third of chondrosarcomas [33], which may also impair the maturation of type II collagen. The
down-regulated expression of the ACAN gene, another important ECM protein, by IDH1
R132C may also have contributed to the fragile structure of cell pellets (Fig 2). Therefore,
although cartilaginous tumors are defined as tumors that produce cartilage-like tissues, the
matrix produced may be immature, which may help tumor cells to proliferate and invade sur-
rounding tissues.
The introduction of an IDH2 R172K mutation, the main IDH2mutation in gliomas, into
C3H10T1/2 was previously shown to reduce the expression of the COL2A1 gene and gave rise
to poorly differentiated sarcomas in xenograft models [34]. We currently cannot explain the
reason for this discrepancy. In order to determine whether this was caused by differences in
donor cells, we introduced IDH1 R132C into C3HT101/2 cells, and found that IDH1 R132C
up-regulated the expression of the Col2a1 gene in mouse cells (data not shown). Therefore,
this difference may be related to the type of mutation (IDH1 R132C versus IDH2 R172K),
which may affect enzymatic activity, as reported previously [35].
The specific occurrence of IDHmutations in cartilaginous tumors among mesenchymal
tumors is another issue that needs to be clarified [16]. Although osteosarcomas are the most
frequent primary malignant bone tumors, no patients with IDH1mutations have been
described in previous and current studies on osteosarcomas. Osteosarcomas and chondrosar-
comas share some clinical phenotypes: both develop from bone marrow in most cases and are
diagnosed by the presence of a specific extracellular matrix. They also share some genetic
abnormalities such as chromosomal aneuploidy and alteration in the Rb and p53 pathways
[33,36]. However, the incidence of IDHmutations clearly differs.
We demonstrated that IDH1 R132C induced the expression of early markers, the RUNX2
and OSX genes, whereas that of the ALPL gene was markedly inhibited, and is the key enzyme
initiating ECMmineralization. Osteogenic properties are one of most important diagnostic fea-
tures of osteosarcomas [17], and, therefore, the inhibitory effect of IDH1 R132C on osteogenic
differentiation may interfere tumor cells to be diagnosed as osteosarcoma.
The gene-specific effects of IDH1 R132C was an interesting finding. IDH1 R132C increased
histone methylation in both cartilage- and bone-related genes as well as global histone methyla-
tion. However, target modifications, either active or repressive, markedly differed in a gene-spe-
cific manner, and ultimately had different effects on the expression of each gene. We currently
have no data to explain the mechanism underlying this gene-specific regulation, but consider
this an important issue for understanding the effects of IDHmutations on the differentiation of
various types of cancers.
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Supporting Information
S1 Fig. IDH1/2mutations in cartilaginous tumors. Three types of IDH1mutations (R132C,
R132G, R132H) and three types of IDH2mutations (R172S, R172T, R172W) were detected in
77 cartilaginous tumors.
(PDF)
S2 Fig. The proliferation of hMSCs expressing IDH1WT or R132C. Each type of hMSC was
plated in 96-well plates at 1000 cells per well. On day 1 and 8, the cell numbers in triplicate
wells were measured as the absorbance at 450 nm of reduced CCK-8. , p<0.05 by Dunnett`s
multiple comparisons test compared to the parental cells. Par, EV, WT, and R132C were as
described in legend for Fig 1.
(PDF)
S3 Fig. Epigenetic modifications to histones associated with the enhancer region of the
COL2A1 gene. Active and repressive histone marks associated with the enhancer region of the
COL2A1 gene in each hMSC were analyzed by ChIP using the antibodies against H3K4me3,
H3K9me3, and H3K27me3. The target region was shown in the scheme at the top of each
graph. Data were presented by qPCR, and the values were indicated relative to the input. Error
bars reflect SD in 3 experiments. TSS, transcription start site. , p<0.01 by Dunnett`s multiple
comparisons test compared to the parental cells. Par, EV, WT, or R132C were as described in
the legend for Fig 1.
(PDF)
S4 Fig. Knock-down of the SOX9 gene in IDH1 R132C hMSCs. hMSCs expressing IDH1
R132C were treated with siRNA targeting SOX9 for 48 hours, and the expression of the SOX9
gene as well as the COL2A1 gene was analyzed by qPCR. Two different siRNAs targeting the
SOX9 gene were used. , p<0.01 by Dunnett`s multiple comparisons test compared to the n.c
(negative control) cells.
(PDF)
S1 Table. Primer sequences used in qRT-PCR.
(PDF)
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